

Paxlovid® – Oral antiviral authorised for the treatment of COVID-19



In January of this year, the EMA granted a conditional marketing authorisation (CMA) valid throughout the EU for the oral antiviral medicine Paxlovid® for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. [Click here](#), or [click the PDF below](#) to read the full document